In our previous study, treatment with a PRMT5 inhibitor EPZ015666 suppressed pressure overload-induced cardiac hypertrophy [27], indicating that PRMT5 in cardiomyocytes may accelerate the cardiac hypertrophy and systolic dysfunction caused by pressure overload. Here, PRMT5 is linked to cardiac hypertrophy.